How Analysts Feel About Recro Pharma, Inc. (REPH) After Today’s Big Increase?

March 14, 2018 - By Maria Brooks

Investors sentiment decreased to 1.65 in 2017 Q3. Its down 0.56, from 2.21 in 2017Q2. It worsened, as 7 investors sold Recro Pharma, Inc. shares while 10 reduced holdings. 5 funds opened positions while 23 raised stakes. 9.63 million shares or 4.72% less from 10.10 million shares in 2017Q2 were reported.
American Grp reported 9,133 shares or 0% of all its holdings. Goldman Sachs Group Inc Incorporated has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 56,658 shares. Opus Point Partners Mgmt has invested 0.2% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH). Savings Bank Of America Corp De holds 0% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH) for 55,745 shares. 21,784 were reported by Jpmorgan Chase & Com. California Public Employees Retirement Systems holds 64,300 shares. Bb&T Corporation stated it has 50,000 shares or 0.01% of all its holdings. Commercial Bank Of Mellon Corp reported 52,391 shares. Panagora Asset Management reported 0% stake. Tower Research Capital Lc (Trc) holds 2,895 shares or 0% of its portfolio. Morgan Stanley reported 0% in Recro Pharma, Inc. (NASDAQ:REPH). Cadence Capital Ltd Limited Liability Company holds 0.09% or 167,637 shares in its portfolio. Legal & General Grp Inc Public Limited Com holds 2,026 shares. Rhumbline Advisers invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Carl Domino holds 0.31% or 28,000 shares in its portfolio.

Since December 12, 2017, it had 0 insider purchases, and 5 insider sales for $1.43 million activity. 93,237 shares were sold by Broadfin Healthcare Master Fund Ltd, worth $919,128 on Tuesday, December 12. 1,579 shares valued at $13,956 were sold by SCP Vitalife Partners (Israel) II – L.P. on Thursday, January 4.

The stock of Recro Pharma, Inc. (NASDAQ:REPH) is a huge mover today! The stock increased 8.19% or $0.85 during the last trading session, reaching $11.23. About 581,041 shares traded or 221.32% up from the average. Recro Pharma, Inc. (NASDAQ:REPH) has risen 26.61% since March 14, 2017 and is uptrending. It has outperformed by 9.91% the S&P500.
The move comes after 6 months positive chart setup for the $215.13 million company. It was reported on Mar, 14 by We have $12.02 PT which if reached, will make NASDAQ:REPH worth $15.06 million more.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on May, 10. They expect $-0.68 earnings per share, down 61.90 % or $0.26 from last year’s $-0.42 per share. After $-0.63 actual earnings per share reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 7.94 % negative EPS growth.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

Among 9 analysts covering Recro Pharma (NASDAQ:REPH), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma had 16 analyst reports since August 25, 2015 according to SRatingsIntel. The rating was initiated by TH Capital with “Buy” on Friday, September 16. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Thursday, November 9 by Roth Capital. The rating was initiated by Janney Capital with “Buy” on Monday, August 29. Piper Jaffray maintained the shares of REPH in report on Wednesday, February 28 with “Buy” rating. As per Wednesday, September 2, the company rating was initiated by H.C. Wainwright. The rating was maintained by Piper Jaffray on Tuesday, July 25 with “Buy”. As per Tuesday, August 25, the company rating was upgraded by Zacks. Oppenheimer initiated the shares of REPH in report on Tuesday, February 13 with “Buy” rating. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Monday, October 3 by Brean Capital. H.C. Wainwright initiated the stock with “Buy” rating in Tuesday, November 24 report.

More important recent Recro Pharma, Inc. (NASDAQ:REPH) news were published by: which released: “Recro Pharma Reports Year End 2017 Financial Results” on February 27, 2018, also published article titled: “Recro Pharma Announces Commercial Team Additions”, published: “Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam …” on February 20, 2018. More interesting news about Recro Pharma, Inc. (NASDAQ:REPH) was released by: and their article: “Recro Pharma to Present at Upcoming Investor Conferences” with publication date: March 06, 2018.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $215.13 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.